Displaying 177 (all) recruiting clinical trials.
-
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
The main goal of this phase III study is to evaluate whether adjuvant therapy with crizotinib (an ATP blocker of several tyrosine kinases) will result ...
-
Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
The purpose of this phase I study is to evaluate the safety and tolerability of MK-3475 (Pembrolizumab), a PD-1/PD-L1 blocking agent in patients with ...
-
S1418/BR006 A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.
If you have been diagnosed with triple negative breast cancer (TNBC) you may qualify to participate in a clinical trial investigating the investigational drug MK-3475 ...
-
A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)
The main goal of this study is to determine if limited surgery or high dose precision radiation is better in patients who are at an ...
-
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
If you have been diagnosed with colon or rectal cancer, you may qualify to participate in a study evaluating the combination of the drugs eflornithine ...
-
Phase II: Adaptive De-escalation of Radiation Therapy Dose In Favorable Risk HPV-Positive Oropharyngeal Carcinoma (ART)
The main goal of this study is to determine if deescalating chemoradiation treatment based on early tumor shrinkage at mid-treatment can result in similar cancer ...
-
HEAD START 4: NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS
If your child has been diagnosed with medulloblastoma or other central nervous system embryonal tumors, your child may qualify to participate in a study. The ...
-
A Phase I Open Label Study of GSK3359609 Administered alone in Combination with Anticancer Agents in Subjects with Selected Advanced Solid Tumors
If you have been diagnosed with selected advanced or recurrent solid tumors including bladder cancer, cervical cancer, colorectal cancer, esophageal cancer with squamous cell histology ...
-
A phase II study of lenvatinib a multi-targeted tyrosine kinase inhibitor combined with pembrolizumab (PD-1 inhibitor) for the treatment of metastatic gastroesophageal cancer patients who have progressed on first or subsequent line therapies
If you have been diagnosed with gastroesophageal, stomach, or gastroesophageal junction (GEJ) cancers, you may qualify for this clinical trial. The goal of this phase ... -
A phase II open-label single arm trial of nivolumab ipilimumab and short-course radiotherapy in adults with newly diagnosed MGMT unmethylated glioblastoma
If you have been diagnosed with a form of brain cancer called glioblastoma and you have not received any therapy for your tumor other than ...